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a B s t r a C t
anaemia is common in older individuals and, because of 
its association with various negative outcomes, adequate 
diagnosis and treatment is important. the present review 
focuses on prominent factors included in diagnostic and 
therapeutic algorithms for anaemia. 
although pernicious anaemia is associated with severe 
vitamin B12 deficiency, evidence of an association between 
subnormal vitamin B12 and anaemia in older persons 
in the general population is limited and inconclusive. 
accumulating evidence suggests that clinicians should at 
least reconsider the risks of a low vitamin B12 level before 
starting vitamin B12 supplementation in older individuals. 
although clinicians may be reluctant to measure ferritin 
in older individuals due to its acute phase properties, 
such measurements are important in older persons with 
anaemia, especially in those with signs of inflammation. 
While a severe age-related decline in renal function may 
lead to a blunted erythropoietin response and anaemia, 
elevated erythropoietin levels are associated with increased 
mortality. More studies are needed to identify the clinical 
relevance and therapeutic implications of low and high 
erythropoietin levels in older persons. in contrast to other 
age-related diseases, telomere length is not associated with 
anaemia in older individuals in the general population.
in conclusion, many issues regarding the aetiology of 
anaemia in old age remain unresolved. Because current 
guidelines on anaemia are based on the classic notions of 
the aetiology of anaemia, they may need to be revised for 
the highest age groups. 
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i n t r o d U C t i o n 
Anaemia is very common in older individuals. The 
reported prevalence ranges from <3% in healthy persons 
aged ≥65 years to 61% in older patients newly admitted 
to geriatric wards.1,2 This wide variance can be due to 
various definitions of anaemia, and to large differences 
in study populations with respect to gender, age, race, 
living situation, and health status.1,2 In the Third National 
Health and Nutrition Examination Survey (NHANES III), 
a nationally representative study of non-institutionalised 
civilian adults in the USA, the overall prevalence of 
anaemia among adults aged ≥65 years was 11.0% in 
men and 10.2% in women.3 In that study, anaemia was 
defined according to World Health Organisation criteria 
(haemoglobin concentration ≤12 g/dl in women and ≤13 
g/dl in men).4 Interestingly, the prevalence of anaemia 
increased significantly with age, i.e. up to 26.1% in men 
and 20.1% in women aged 85 years and over.3 
In older persons, anaemia is associated with impaired 
survival,5-10 decreased physical performance, disability in 
daily living, cognitive impairment, depression, diminished 
quality of life, and with an increased number of hospital 
admissions.1,11-21 Considering the steep increase in the 
prevalence of anaemia in older individuals, and the 
exponential rise in the number of older individuals in our 
ageing society, anaemia in older individuals may have a 
significant impact on healthcare needs and costs in the 
future.22 Adequate diagnosis and treatment of anaemia in 
older persons is therefore of vital importance. 
In clinical practice, older patients with anaemia are 
carefully examined to detect and treat the underlying cause 
of the anaemia. Treating physicians will enquire about 
recent blood loss, signs and symptoms from the digestive 
tract, nutritional habits, weight loss, and drugs and 
alcohol intake.23 In most diagnostic laboratory algorithms 
for anaemia, the mean corpuscular volume (MCV) plays 
a central role.23-25 In patients with microcytic anaemia 
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(MCV <80 fl), ferritin, iron and transferrin levels are 
measured to determine the presence of iron deficiency 
anaemia. Vitamin B12 and folate are measured in patients 
with macrocytic anaemia (MCV >100 fl) to determine or 
rule out the presence of vitamin B12 or folate deficiency. 
Normocytic anaemias (MCV 80-100 fl) are often caused 
by chronic diseases, malignancies or bone marrow 
conditions.23-25 
Anaemia is a unique condition in the sense that diagnostic 
and therapeutic guidelines are based on assumed aetiology 
and pathophysiology. Interestingly, most studies on 
anaemia have been performed in selected patient groups 
(e.g. patients in hospital wards and residents in institutions 
for older persons) and not in very old persons from 
the general population. Increasingly, data have become 
available that question the extrapolation of ‘common’ 
medical knowledge to the highest age groups. For instance, 
the effects of some classical determinants of disease and 
mortality in middle age (e.g. hypothyroidism, hypertension 
and hypercholesterolaemia) have been shown to disappear 
or even reverse in the oldest old,26-29 indicating that 
physiological processes in the oldest old may be distinct 
from those in younger individuals. 
The present review focuses on some of the most prominent 
factors included in diagnostic and therapeutic algorithms 
for anaemia to assess whether these factors also apply for 
older persons in the general population. 
a e t i o l o G Y  o f  a n a e M i a
Vitamin B12 deficiency
Pernicious anaemia is a form of anaemia that is undeniably 
associated with severe vitamin B12 deficiency. Finding the 
cure for pernicious anaemia in fact led to the discovery 
of vitamin B12.30-36 Undoubtedly, patients with very low 
vitamin B12 concentrations (in case of pernicious anaemia) 
have to be treated. Patients with pernicious anaemia or 
food-vitamin B12 malabsorption show large increases in 
haemoglobin after vitamin B12 administration.37-40 
The outcomes of studies in patients with pernicious 
anaemia are often extrapolated to patients with subnormal 
vitamin B12 concentrations in the general population. 
As a result, subnormal vitamin B12 concentrations 
are considered to be associated with (mild) anaemia in 
general, but also with other conditions such as dementia, 
neuropathy and subacute combined degeneration of the 
spinal cord.41-44 Therefore, physicians routinely measure 
vitamin B12 in patients with anaemia. Individuals with 
low serum concentrations of vitamin B12 (and normal 
folate concentrations) are frequently given intramuscular 
vitamin B12 supplements, often for many years.23,43,44 
Also, since low serum vitamin B12 concentrations are very 
common in older individuals,45 screening older people for 
vitamin B12 deficiency has often been recommended.46,47 
However, although the biological role of vitamin B12 in 
haematopoiesis is well defined,44,48-50 current evidence 
suggests that the outcomes of these studies in patients with 
severe vitamin B12 deficiency should not be extrapolated 
to patients with subnormal vitamin B12 concentrations in 
the general population. 
results from the leiden 85-plus study
In the Leiden 85-plus Study, a population-based prospective 
follow-up study of 85-year-old individuals (living in 
Leiden, the Netherlands), we showed that low vitamin B12 
concentrations (<150 pmol/l) in 85-year-old persons are not 
associated with the presence of anaemia at age 85 years.51 
Also, participants with low vitamin B12 concentrations 
did not have a higher risk to develop anaemia from age 85 
onwards (figure 1). Adjustment for possible confounders did 
not change our results.51 
results of a systematic literature review
Interestingly, our study was not the first to cast doubt 
on the relationship between subnormal vitamin B12 
concentrations and anaemia in older individuals. In 
a systematic review of the literature, we evaluated the 
association between subnormal vitamin B12 concentrations 
and anaemia in older people.52 Twenty-two observational 
studies showed inconsistent results with regards to the 
association between subnormal vitamin B12 concentrations 
or vitamin B12 deficiency and anaemia in older subjects. 
Three randomised placebo-controlled trials (RCTs), with 
figure 1. Effect of vitamin B12 deficiency (<150 pmol/l) 
on anaemia during follow-up in subjects without 
anaemia at age 85 years (n=313); hazard ratio 0.85; 
95% confidence interval 0.43-1.65.51 Reprinted with 
permission. Arch Intern Med 2008;168(20):2241. 
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a total of 210 participants, met the inclusion criteria for 
intervention studies for our review.53-55 Due to clinical 
heterogeneity (differences in methods of administration, 
dose of vitamin B12, outcome measures and treatment 
follow-up time) we did not combine the results in a 
meta-analysis. However, the three RCTs (considered to be 
of methodologically high quality) showed no beneficial 
effect of vitamin B12 administration on haemoglobin 
concentrations, MCV, cognitive function and neurological 
symptoms.53-55 Moreover, there was no treatment effect for 
participants who were anaemic.54
Clinical implications and implications for future research 
Taking these findings into account, one may conclude 
that strong evidence is lacking for a positive association 
between subnormal vitamin B12 concentrations and 
anaemia in older persons in the general population. The 
above-mentioned findings do not imply that patients with 
pernicious anaemia or food-vitamin B12 malabsorption 
(with tissue depletion of vitamin B12 and very low vitamin 
B12 concentrations) should be withheld from vitamin B12 
administration.38,39 However, apart from the undisputed 
reality of pernicious anaemia, the clinical impact of a 
subnormal vitamin B12 concentration in older persons 
in the general population remains unclear. The fact that 
several observational studies and RCTs also showed 
no effect of vitamin B12 administration on cognitive 
function raises even more doubt about the consequences 
of subnormal vitamin B12 concentrations in older persons 
in the general population.56-58
Many older persons in primary care may receive vitamin 
B12 injections without evidence for clinical improvement. 
In addition, these findings raise doubt about the value 
of vitamin B12 measurement in diagnostic guidelines 
for anaemia as this may distract attention from other 
possible underlying causes. If a subnormal vitamin 
B12 concentration is not the cause of the anaemia, 
supplementation with vitamin B12 will not lead to a rise in 
haemoglobin concentration. Additional proof of the (lack 
of) effectiveness of vitamin B12 treatment in older patients 
with anaemia and subnormal vitamin B12 concentrations 
should come from a randomised double-blind placebo-
controlled trial. However, before such a trial is performed, 
this accumulating evidence suggests that clinicians 
should at least reconsider the risks of a low vitamin 
B12 concentration before starting cyanocobalamin or 
hydroxocobalamin supplementation in older individuals.59 
Interestingly, in contrast to vitamin B12, folate deficiency 
is still associated with anaemia in older individuals.51 
Early detection of folate deficiency by screening may 
identify older individuals at risk of developing anaemia. 
The biochemical pathways suggest that folic acid 
supplementation is beneficial, but it remains unclear 
whether folic acid fortification of grain and cereal products 
(as employed in the USA60,61) has a positive effect on the 
incidence of anaemia in older persons and should also be 
employed in the Netherlands.62 This is a topic for future 
studies.
iron deficiency and inflammation
Iron deficiency is a common cause of anaemia, being 
found in ≥15% of older persons with anaemia.3,24,63 Serum 
ferritin levels strongly correlate with body iron stores64,65 
and are considered the best noninvasive test for the 
diagnosis of iron deficiency.63,66,67 Therefore, ferritin plays 
a central role in diagnostic and therapeutic algorithms for 
iron-deficiency anaemia in clinical practice.23-25 
results of the leiden 85-plus study
Ferritin is also a well-known acute phase protein and 
may be elevated in acute and chronic inflammatory 
conditions, such as (respiratory tract) infections, 
rheumatoid arthritis and cancer.63,68,69 In case of acute and 
chronic inflammatory conditions, serum ferritin may not 
accurately reflect true iron status.63,68,69 Clinicians may be 
reluctant to measure ferritin in older individuals, especially 
in those with infections or inflammation; however, 
findings from the Leiden 85-plus Study suggest that 
ferritin measurements are important in these persons.70 
Low ferritin was associated with lower haemoglobin levels 
and lower MCV, but this association was more pronounced 
in participants with elevated C-reactive protein (CRP) levels 
than in subjects with normal CRP levels. It is hypothesised 
that low ferritin is such a specific marker of iron status 
in individuals with inflammation due to its ‘acute phase’ 
properties, i.e. iron status must be poor when low ferritin 
levels are found in the presence of inflammation.70 
Potential role for hepcidin
It has been hypothesised that upregulation of hepcidin (the 
main regulator of iron homeostasis) plays an important 
role in the anaemia of inflammation. 
An inflammatory stimulus activates monocytes and T cells 
to produce pro-inflammatory cytokines.71 These cytokines, 
particularly interleukin 6, induce the production and 
secretion of hepcidin by hepatocytes.72 Hepcidin binds to 
the membrane protein ferroportin, an iron efflux channel 
on the surface of absorptive enterocytes, macrophages 
and hepatocytes, and induces its internalisation and 
degradation in lysosomes, thereby blocking the export 
of iron from cells.73 Consequently, duodenal enterocytes 
deliver less dietary iron to extracellular fluid, macrophages 
fail to release iron recycled from senescent erythrocytes 
and hepatocytes retain stored iron, leading to a rapid 
drop in iron levels,74 iron-restricted erythropoiesis, and 
anaemia.71,75,76 Moreover, transgenic mice overexpressing 
hepcidin and mice receiving synthetic hepcidin develop 
mild-to-moderate microcytic, hypochromic anaemia.77-80 
263
j u n e  2 0 1 1 ,  v o l .  6 9 ,  n o  6
Den Elzen, et al. Anaemia in older persons. 
As a result, hepcidin is considered to be the main mediator 
of anaemia of inflammation,75,81,82 also known as anaemia of 
chronic disease, which is commonly found in patients with 
chronic infections or with inflammatory disorders, such as 
rheumatoid arthritis, inflammatory bowel disease, cancer 
and chronic kidney disease.71,83,84 Although a preliminary 
analysis in the InChianti study (a population-based study 
of older persons in Tuscany, Italy) could not demonstrate 
higher urinary hepcidin levels in older individuals with 
anaemia of inflammation,85 this hypothesis should still 
be tested in other population-based prospective follow-up 
studies, preferably using serum hepcidin assays which have 
recently become available.86,87 Depending on the outcomes 
of these additional studies, future diagnostic algorithms 
for anaemia may incorporate markers of inflammation 
such as CRP or even hepcidin to discriminate between 
classic iron-deficiency anaemia (low hepcidin levels) and 
iron-deficiency anaemia in the context of anaemia of 
inflammation or chronic disease (elevated hepcidin levels).87 
The results of these studies may also lead to innovative 
clinical trials, for instance by treating older patients with 
anaemia of inflammation with anti-inflammatory agents or 
hepcidin antagonists such as agents that inhibit hepcidin 
production (e.g. anti-interleukin 6 receptor antibodies), 
hepcidin neutralising antibodies, targets against hepcidin 
binding site of ferroportin or agents that inhibit ferroportin 
internalisation.83,88
erythropoietin
Renal function, erythropoietin and anaemia
Decreased oxygen availability in the kidney triggers the 
production of erythropoietin (the principal regulator of 
red blood cell mass) by the peritubular capillary lining 
cells within the kidney.89 Impaired oxygen delivery to 
the kidney can result from various pathophysiological 
mechanisms, such as anaemia, hypoperfusion due to renal 
arteriosclerosis, lowered renal blood flow or heart failure, 
or decreased oxygen saturation due to diseases such as 
chronic obstructive pulmonary disease.89-93 In the InChianti 
study, participants with a creatinine clearance of 30 ml/
min or lower had significantly lower age and haemoglobin-
adjusted endogenous erythropoietin levels than their 
counterparts with normal renal function.94 Thus, severe 
age-related decline in renal function may lead to a blunted 
erythropoietin response and anaemia.94 It is also known that 
erythropoietin substitution therapy is effective in raising 
haemoglobin levels and improving the quality of life in (pre)
dialysis, cancer patients, and also in community-dwelling 
older persons with unexplained chronic anaemia.95-99
Erythropoietin and mortality
Interestingly, studies in chronic heart failure patients 
indicated that high erythropoietin is a predictor 
of impaired survival.100-105 In addition, in the Leiden 
85-plus Study, we also observed a dose-dependent 
positive association between increasing erythropoietin 
levels and mortality, independent of gender, creatinine 
clearance, haemoglobin level, comorbidity, smoking and 
C-reactive protein level.106 It is not exactly clear why 
elevated erythropoietin levels mark excess mortality. 
Elevated erythropoietin levels could be a physiological 
response to a chronically increased hypoxic stimulus 
due to yet undiagnosed subclinical disease.107,108 Elevated 
erythropoietin may also be compensating for removal 
of erythrocytes from the blood, either because of 
erythrocyte fragility, subclinical chronic haemolysis, or 
blood loss.107,108 Further studies are needed to shed light 
on the mechanisms involved and to identify the clinical 
and therapeutic implications of a high erythropoietin 
level in old age, especially since a number of unexpected 
nonhaematopoietic functions of erythropoietin 
have recently been identified.109 Our findings do not 
necessarily implicate that older individuals with renal 
failure, cancer or unexplained anaemia should not be 
treated with recombinant erythropoietin. However, recent 
meta-analyses of randomised trials showed that treatment 
with erythropoiesis-stimulating agents in patients with 
chronic kidney disease or cancer had a negative influence 
on survival,110-112 which clearly emphasises the need for 
further studies on the aetiology and effects of high 
erythropoietin levels in older individuals.
Unexplained anaemia
In approximately one third of older patients with anaemia, 
the cause of the anaemia is unknown; their anaemia is 
‘unexplained’.3 Since older subjects with unexplained 
anaemia often present with low leucocyte counts,113,114 
myelodysplastic syndromes or other types of bone marrow 
failure may be the underlying diagnosis for unexplained 
anaemia.3,114-116 
Telomere length and anaemia
Telomeres are DNA-protein complexes at the ends of 
chromosomes. Telomeres are critical for chromosome 
stability and function, since they protect chromosome ends 
against fusion, degradation and recombination. In somatic 
and haematopoietic cells, telomeres shorten with every 
cell division as a result of the end-replication problem (i.e. 
the inability of the DNA replication machinery to replicate 
the lagging DNA strand after removal of the RNA primer) 
and oxidative damage.117 Telomerase can preserve telomere 
length by adding de novo tandem repeats at chromosome 
ends, but its activity in somatic cells and haematopoietic 
progenitor cells is very low. Consequently, mean somatic 
cell and peripheral blood mononuclear cell telomere length 
shortens with age.117 When telomere length falls below a 
critical level, replicative senescence (permanent growth 
arrest) is induced.118,119 
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Telomere length is considered a marker of biological and 
cellular ageing and has been correlated with a number 
of major age-related diseases such as dementia,120-123 
myocardial infarction,124 heart failure,125 atherosclerosis,126 
and solid tissue tumours.127
Myelodysplastic syndromes or other types of bone marrow 
failure are thought to explain the increased frequency of 
(unexplained) anaemia in older individuals.3,115,116 Adult 
haematopoietic stem cells show a severe loss of telomeric 
DNA compared with cells from foetal liver or umbilical cord 
blood,128 and aged mice have a decreased capacity to replace 
blood cells during haematopoietic stress compared with 
younger mice,115,129 indicating a loss of replicative potential 
for bone marrow stem cells with age128,130 and a possible 
incapacity to react to the physiological demand for blood cell 
replenishment with age.115,116,129 Since earlier studies indicate 
that patients with myelodysplastic syndromes or other 
types of bone marrow failure syndromes have shortened 
telomeres,131-133 shorter telomere length has been associated 
with an increased risk of anaemia in chronic heart failure 
patients134 and was an independent predictor of lower 
red blood cell counts in a study of middle-aged subjects 
(aged 35-55 years),135 telomere length may be a marker of 
haematopoietic ageing and bone marrow failure and, as a 
result, may be associated with anaemia in older individuals 
in the general population. Therefore, we investigated the 
relation between telomere length and the presence of 
anaemia (and unexplained anaemia in particular) in two 
population-based studies of individuals aged 85 years and 
over: the Newcastle 85-plus Study, and the Leiden 85-plus 
Study. In both cohorts, no difference was observed in 
telomere length between participants with anaemia and 
without anaemia, nor did telomere length correlate with 
any other haematological parameter.136 Thus, in contrast to 
other age-related diseases, telomere length is not associated 
with anaemia or any other haematological parameter in 
older individuals in the general population, despite the 
plausible biological mechanism underlying this association. 
Our findings are supported by another study in which no 
correlation was found between telomere length and blood 
counts in a population-based sample of 717 women aged 
38 to 100 (median 72) years.137 To further investigate this 
intriguing matter, studies incorporating bone marrow 
biopsies are needed. 
C o n C l U d i n G  r e M a r K s
Although researchers and clinicians have paid much 
attention to the clinical implications and pathophysiology 
of anaemia in older individuals, the consequences and 
underlying pathophysiological mechanisms of anaemia 
in the oldest old in the general population are still 
relatively unknown. However, it has become clear that, 
while folate deficiency at age 85 years is still associated 
with the development of anaemia during follow-up, this 
does not seem to be the case for vitamin B12 deficiency. 
Nowadays, many older subjects with subnormal 
vitamin B12 concentrations receive hydroxocobalamin 
treatment. Further trials are needed to verify whether 
older individuals with anaemia and subnormal vitamin 
B12 levels should be treated with hydroxocobalamin. 
Furthermore, in old age, low ferritin is associated with the 
presence of anaemia, particularly in older persons with 
elevated CRP levels, indicating that ferritin measurements 
are still important, especially in older persons with 
signs of inflammation. Serum hepcidin measurements 
may elucidate the complicated interrelation between 
iron deficiency, inflammation and anaemia. Additionally, 
severe age-related decline in renal function may lead to a 
blunted erythropoietin response and anaemia. Elevated 
erythropoietin levels are associated with increased 
mortality, independent of haemoglobin and other 
comorbidities. Additional studies are needed to identify 
the clinical relevance and therapeutic implications of a 
low and a high erythropoietin level in older people in 
the general population. Moreover, in contrast to other 
age-related diseases, telomere length is not associated with 
anaemia in older individuals in the general population, 
despite the plausible biological mechanism underlying 
this association. 
Finally, future studies should focus on improving the 
diagnostic algorithms for anaemia in older individuals 
by examining the additional diagnostic value of 
erythropoietin, homocysteine, methylmalonic acid, CRP 
or hepcidin in these algorithms. Since the prevalence of 
anaemia is highest in the highest age groups, more studies 
are needed to elucidate the specific causes of anaemia in 
these age groups. As current diagnostic and therapeutic 
guidelines are based on the classic notions of the aetiology 
of anaemia, the guidelines on anaemia may have to be 
revisited for the highest age groups in the coming years. 
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